Navigation Links
Pharmacopeia Announces Positive Results from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA)
Date:9/12/2007

eloped as a potential treatment for hypertension and diabetic nephropathy. PS433540, the first and only DARA compound in development, possesses two clinically validated mechanisms of action in a single compound. There is considerable preclinical and initial clinical data suggesting that compared to either agent alone, simultaneously blocking the actions of both AII and ET1 may provide significantly improved treatment options for several cardiovascular diseases.

ABOUT PHARMACOPEIA

Pharmacopeia is committed to discovering and developing novel therapeutics to address significant medical needs. The Company has a broad portfolio advancing toward clinical validation, both independently and with partners. Pharmacopeia's most advanced internal program is a dual-acting angiotensin and endothelin receptor antagonist (DARA) for hypertension and diabetic kidney disease for which Phase 1 clinical trials are underway. Other internal proprietary programs address primarily immunoregulation. Pharmacopeia's collaborative efforts have resulted in a portfolio that includes one partnered program currently in Phase 2 clinical trials targeting chronic obstructive pulmonary disease (COPD) and three partnered programs in Phase 1 clinical trials targeting rheumatoid arthritis, oncology, and inflammatory disease. Four additional partnered compounds are in preclinical development.

Pharmacopeia's current strategic alliances are with Cephalon, GlaxoSmithKline, Organon and Wyeth.

Contact:

Brian M. Posner

Executive Vice President and Chief Financial Officer

Pharmacopeia, Inc.

(609) 452-3643

ir_pr@pharmacopeia.com

This press release, and oral statements made with respect to information contained in this press release, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those which express plan, a
'/>"/>

SOURCE Pharmacopeia
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Pharmacopeia Announces Positive Results from Initial DARA Clinical Trial
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Sygnis Pharma AG announces date for presentation of clinical results
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... MADISON, N.J. , Oct. 22, 2014  Quest ... provider of diagnostic information services, today announced that its ... Ph.D., to serve as a director, effective December 1, 2014. ... Dr. Leiden is the Chairman, President and CEO ... 20 years of scientific and commercial experience in the ...
(Date:10/22/2014)... , Oct. 22, 2014  Charlene Vernak, RPh, of ... , recently was awarded the George Roentsch Scholarship ... received the award in Houston ... scholarship is awarded annually to an independent pharmacist and ... of George Roentsch , a well-known pharmacist in ...
(Date:10/22/2014)... 22, 2014  Paper Pak Industries, a manufacturer ... ® Body Guard Bio, a disposable, highly ... bacteria and virus while protecting service providers and ... features a rugged, external nylon shell, watertight zipper, ... leak-proof inner chamber that contains contaminated and potentially ...
Breaking Medicine Technology:Quest Diagnostics Adds Jeffrey M. Leiden, M.D., Ph.D., to Board of Directors 2Quest Diagnostics Adds Jeffrey M. Leiden, M.D., Ph.D., to Board of Directors 3PCCA Awards Charlene Vernak, RPh, the George Roentsch Scholarship 2New, State-Of-The-Art Body Bag Minimizes The Spread Of Bacteria And Virus 2
... 27 For the first time ever, large numbers of personnel ... ChemOutsourcing at the Jersey Shore this fall. Most are chemists by training ... , , , ... found a home on the East Coast where the majority of the ...
... 27 BioElectronics Corp. (Pink Sheets: BIEL), manufacturers of ... for Japan , YesDTC Holdings, Inc. (OTC Bulletin Board: ... pending review by Japanese government medical device regulators for the ... place on Wednesday, July 28th . , ...
Cached Medicine Technology:Big Pharma Chemists Turning Out in Large Numbers for ChemOutsourcing Extravaganza Event on September 14-16, 2010 at Jersey Shore Beach Resort 2BioElectronics and YesDTC Holdings Receive Japanese Regulatory Review Date 2
(Date:10/25/2014)... -- A large influx of international aid is needed, ... of thousands of deaths from the widening Ebola crisis, ... Using a specially designed mathematical model, the researchers looked ... one densely populated county of hard-hit Liberia -- Montserrado ... The researchers said that if international aid isn,t delivered ...
(Date:10/25/2014)... Oct. 24, 2014 (HealthDay News) -- October,s shorter, darker ... seasonal affective disorder, according to an expert. ... may feel overly tired, lack motivation and even have ... can lead to suicide, said Dr. Angelos Halaris, a ... at Loyola University Chicago Stitch School of Medicine. ...
(Date:10/22/2014)... On October 22, CBS will air an ... both fictional and real. The Charles E Holman ... to advocacy and philanthropy in the battle against Morgellons ... to impart truth and clarity about this misunderstood and ... misconceptions about Morgellons Disease (MD) and most ...
(Date:10/22/2014)... (PRWEB) October 22, 2014 For Dr. Iris ... make money; it’s an extension of her life’s mission. Her ... venture as the owner of FirstLight HomeCare, make it clear ... important to me that my work makes a difference in ... an entrepreneurial spirit, so after much research, I felt ready ...
(Date:10/22/2014)... 2014 Shriners Hospitals for Children® and ... the current location of Shriners Hospitals for Children - ... from the University of Kentucky Albert B. Chandler Hospital. ... center, owned and operated by Shriners Hospitals for Children, ... children and their families well into the future. , ...
Breaking Medicine News(10 mins):Health News:Experts Predict 'Catastrophic' Ebola Epidemic in West Africa if Aid Delayed 2Health News:Dark Days Here for Folks With Seasonal Depression 2Health News:CBS’ Criminal Minds takes aim at skin disease with Morgellons in the Mix 2Health News:CBS’ Criminal Minds takes aim at skin disease with Morgellons in the Mix 3Health News:Dr. Iris Hunter to Host Grand Opening of FirstLight HomeCare Tomorrow 2Health News:Shriners Hospitals for Children - Lexington Announces Plan to Build New $47 Million Facility 2Health News:Shriners Hospitals for Children - Lexington Announces Plan to Build New $47 Million Facility 3
... an incidence rate between 0 and 2.6% (average 0.3%) in ... generally well tolerated by patients, causing a delay in medical ... pediatrician faced with diagnosis and treatment of tinea of the ... tinea of the nails was observed in the Hospital del ...
... wellbeing in rich countries might depend more on reductions in ... study published today on bmj.com . , Poorer ... But a recent UNICEF report detailing 40 indicators of ... fared worse than in any of the other rich countries. ...
... Treatment ... Worldwide, LOS ANGELES, Nov. ... develop an AIDS vaccine have,announced that their efforts have stumbled or, in ... was halted last week,when its vaccine was suspected of actually making some ...
... Patients Ages 10 to 17 ... ... ,Otsuka Pharmaceutical Co., Ltd. and Bristol-Myers Squibb Company (NYSE:,BMY) announced today that ... a Priority Review to the supplemental New,Drug Application (sNDA) of the atypical ...
... care fraud,becoming more organized, sophisticated, and prevalent, ... Investigative Units,(SIUs), state and federal agencies, and ... Health Care Anti-Fraud Association (NHCAA),s Annual,Training Conference, ... learn,more about new fraud schemes and explore ...
... against prescribing drug to patients who are already depressed ... take the weight-loss drug rimonabant may face heightened risks ... The finding follows a recommendation by a U.S. Food ... not approve the diet drug because of continuing concerns ...
Cached Medicine News:Health News:Tinea of the nails underdiagnosed in children 2Health News:Low standards of child well-being linked to greater income inequality 2Health News:AIDS Vaccine Failures Highlight Need to Focus on Lifesaving Treatment, Says AHF 2Health News:ABILIFY(R) (aripiprazole) Supplemental New Drug Application for the Treatment of Pediatric Patients with Bipolar I Disorder Accepted for Priority Review by the U.S. Food and Drug Administration 2Health News:ABILIFY(R) (aripiprazole) Supplemental New Drug Application for the Treatment of Pediatric Patients with Bipolar I Disorder Accepted for Priority Review by the U.S. Food and Drug Administration 3Health News:ABILIFY(R) (aripiprazole) Supplemental New Drug Application for the Treatment of Pediatric Patients with Bipolar I Disorder Accepted for Priority Review by the U.S. Food and Drug Administration 4Health News:ABILIFY(R) (aripiprazole) Supplemental New Drug Application for the Treatment of Pediatric Patients with Bipolar I Disorder Accepted for Priority Review by the U.S. Food and Drug Administration 5Health News:ABILIFY(R) (aripiprazole) Supplemental New Drug Application for the Treatment of Pediatric Patients with Bipolar I Disorder Accepted for Priority Review by the U.S. Food and Drug Administration 6Health News:NHCAA Annual Training Conference Bringing Together Law Enforcement, Health Insurers to Fight Health Care Fraud 2Health News:NHCAA Annual Training Conference Bringing Together Law Enforcement, Health Insurers to Fight Health Care Fraud 3Health News:Diet Drug Rimonabant Tied to Depression, Anxiety 2Health News:Diet Drug Rimonabant Tied to Depression, Anxiety 3
Synchron CX3 Delta is a critical care clinical system, providing unparalleled testing speed for the most frequently ordered chemistries-Glucose, BUN, Creatinine, Sodium, Potassium Chloride, CO2 Calci...
Iron (Total/Ferene). Storage temp: 15 - 30 C. Linearity: 0 - 500 ug/dl. Expected values: from males 60 - 160 ug/dl, from females 43 - 140 ug/dl. Available with Calibrator and Number of test are 120....
For the quantitative determination of iron, total iron-binding capacity in human serum....
HDL Cholesterol, liquid....
Medicine Products: